Paoli F, Spignoli G, Pepeu G
Department of Preclinical and Clinical Pharmacology, University of Florence, Italy.
Psychopharmacology (Berl). 1990;100(1):130-1. doi: 10.1007/BF02245803.
Intracerebroventricular administration (6 micrograms/2 microliters) of D-2-amino-5-phosphonovalerate (AP-5), a specific antagonist of the NMDA receptors, prior to training impaired the passive avoidance in a retention test in rat. Pretreatment with oxiracetam and D-pyroglutamic acid at doses ranging from 50 to 500 mg/kg SC dose-dependently prevented the disruptive effect of AP-5. This finding indicates that an interaction with excitatory amino acid NMDA type receptors may be important in behavioural effects of the two pyrrolidinone derivatives.
在训练前向大鼠脑室内注射（6微克/2微升）NMDA受体特异性拮抗剂D-2-氨基-5-磷酸戊酸（AP-5），会损害其在被动回避记忆测试中的表现。以50至500毫克/千克的剂量皮下注射奥拉西坦和D-焦谷氨酸进行预处理，可剂量依赖性地预防AP-5的破坏作用。这一发现表明，与兴奋性氨基酸NMDA型受体的相互作用可能在这两种吡咯烷酮衍生物的行为效应中起重要作用。
